EUVIMEDEUVIMED entdecken
Crossref

Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target

Lixiao Xing, Zhimin Liu, Xinling Wang, Qianying Liu, Wei Xu, Qiyu Mao, Xiang Zhang, Aihua Hao, Shuai Xia, Zezhong Liu, Lujia Sun, Guangxu Zhang und 5 weitere

Cell · 2025-03 · 188 (5) · 1297-1314.e24

DOI: 10.1016/j.cell.2025.01.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2025-03. Verfasst von Lixiao Xing und 16 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Scienc…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangzhou Medical University, Shanghai Municipality Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2SARS-CoV-2Antiviral AgentsVirus InternalizationAnimalsHumansCOVID-19MiceVero CellsHEK293 CellsMembrane FusionChlorocebus aethiops

Stichwörter der Autor:innen

coronavirusdual-functional antiviralsearly fusion intermediate conformationmembrane fusion mechanismspike

Substanzen

Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antiviral Agentsspike protein, SARS-CoV-2ACE2 protein, human

Autor:innen und Institutionen

  • Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Fifth People's Hospital, Institutes of Biomedical Science…
  • Department of Pharmacology & the Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201210, China.

Förderung

  • National Key Research and Development Program of China
  • Guangzhou Medical University
  • Shanghai Municipality Science and Technology Commission
  • Fudan University
  • National Natural Science Foundation of China

Zitieren

APA

Xing, L., Liu, Z., Wang, X., Liu, Q., Xu, W., Mao, Q., Zhang, X., Hao, A., Xia, S., Liu, Z., Sun, L., Zhang, G., Wang, Q., Chen, Z., Jiang, S., Sun, L., & Lu, L. (2025). Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell, 188(5), 1297-1314.e24. https://doi.org/10.1016/j.cell.2025.01.012

Vancouver

Xing L, Liu Z, Wang X, Liu Q, Xu W, Mao Q, et al. Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell. 2025;188(5):1297-1314.e24. doi:10.1016/j.cell.2025.01.012

BibTeX
@article{Xing2025,
  author = {Xing, Lixiao and Liu, Zhimin and Wang, Xinling and Liu, Qianying and Xu, Wei and Mao, Qiyu and Zhang, Xiang and Hao, Aihua and Xia, Shuai and Liu, Zezhong and Sun, Lujia and Zhang, Guangxu and Wang, Qian and Chen, Zhenguo and Jiang, Shibo and Sun, Lei and Lu, Lu},
  title = {Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {5},
  pages = {1297--1314.e24},
  doi = {10.1016/j.cell.2025.01.012}
}
Kostenlos starten →